Dosing‐time‐dependent changes in the efficacy of ICIs are driven by the circadian fluctuation of PD‐1 expression in tumor‐associated macrophages (TAMs) and circadian variation in the infiltration of CD8+ T cells.18, 19. The gene discussed is CD8A; the disease is neoplasm.